LILRB1 and neoplasm: BND-22 (IgG4) for ILT2; MK-4830 (IgG4) for ILT-4; Simultaneous blockade of ILT-2 and ILT-4 is more effective in myeloid cell reprogramming in the TME in 3D tumor spheroids